The Leronlimab approvals for combo open the door t
Post# of 148179
(Total Views: 461)
Posted On: 11/14/2019 4:39:58 AM
The Leronlimab approvals for combo open the door to paradise for CYDY, as this is not just one indication, the ability to use Leronlimab off-label for dozens of cancers with metastases where CCR5 is expressed, as it has been proven effective and safe.
I've been saying this for a long time, when Leronlimab is approved for a combo, Leronlimab will be approved on the market, and no one can ban its use for other indications, the FDA only not allows advertising off-label. We will have an approved drug on the market which has a proven track record of many indications where patients are at risk of life. Leronlimab will also be used as mono because studies prove it, but I expect its widespread use in many cancers with metastasis where CCR5 is expressed. And the need is enormous because many drugs quickly develop resistance and the patient needs something else.
I've been saying this for a long time, when Leronlimab is approved for a combo, Leronlimab will be approved on the market, and no one can ban its use for other indications, the FDA only not allows advertising off-label. We will have an approved drug on the market which has a proven track record of many indications where patients are at risk of life. Leronlimab will also be used as mono because studies prove it, but I expect its widespread use in many cancers with metastasis where CCR5 is expressed. And the need is enormous because many drugs quickly develop resistance and the patient needs something else.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼